QuarterHawkSign in

NRC Health (NRC)

Healthcare

No action
Fundamental
3
Sentiment
2
Technical
2

Do Nothing: qualitativeScore is 2 (below required floor of 3), and NRC also fails the $5M 20-day average dollar-volume floor.

Analysis as of 2026-08-03· about 2 trading days ago

Company overview

National Research Corporation (NRC) provides data-driven analytics and insights to healthcare organizations in the U.S. and Canada. Their subscription-based solutions enhance patient and employee experiences, focusing on the patient journey, service recovery, and care transitions. NRC also offers market intelligence and segmentation tools for understanding community needs and behaviors.

Fundamental

fair
Fundamental3
Mixed fundamentals

NRC Health's fundamentals are mixed, with high gross margins but declining earnings and tight liquidity.

SEC filings show a working-capital deficit and debt covenants, but management reports covenant compliance and access to unused revolver capacity (10-K filed 2026-03-05; 10-Q filed 2026-05-06). Financial performance has weakened over several years (negative revenue/EBITDA/EPS CAGRs), and valuation/intrinsic-value signals are not supportive (TTM P/E ~74x; DCF indicates ~29–35% downside vs $19.50). Overall: mixed fundamentals and risk/reward → fundamentalScore 3/5.

Sentiment

weak
Sentiment2
Weak sentiment

Sentiment is weak with no clear catalysts and mixed media coverage focused on margin compression.

Dominant near-term catalyst is the Q2 2026 earnings release (2026-07-28, announced), which drove mixed-to-negative coverage centered on margin compression and a widening net loss; the 30–90d sentiment delta is indeterminate due to sparse/low-relevance baseline coverage and Reddit chatter is absent. No regulator-confirmed investigations were found (legal case search was CAPTCHA-blocked), and no severe red flags were identified.

Technical

weak
Technical2
Damaged structure

Technically, the stock is in a damaged structure post-earnings, with no clear catalyst for reversal.

Price is below SMA20/SMA50, EMA9/EMA21, WMA9/WMA21 and daily VWAP after a failed earnings spike; MACD (-0.28 vs 0.08 signal) is below zero and ADX 45.67 confirms strong trend pressure, with only the SMA200 still acting as longer-term support.

You’re looking at 2026-08-03 — about 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.